云顶新耀医药科技有限公司 EVEREST MEDICINES
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Everest Medicines Announces Signing of an MOU for Strategic Cooperation with Guangdong Academy of Medical Sciences in Renal Diseases 2023-03-23 17:52
Everest Medicines to Announce Full-Year 2022 Financial Results on March 31, 2023 2023-03-15 20:45
Everest Medicines Announces Partner Calliditas Therapeutics Reports Positive Topline Results from Phase 3 NefIgArd Trial Evaluating Nefecon in IgA Nephropathy 2023-03-14 07:30
Everest Medicines Announces Silicon Valley Bank Developments Have Minimal Impact on Company 2023-03-13 07:51
Everest Medicines Hosts Ceremony to Celebrate Commencement of Operations at its State-of-the-Art mRNA Vaccine Manufacturing Facility 2023-02-28 07:30
Everest Medicines Announces South Korea Grants Fast Track Review Designation to Nefecon for the Treatment of Primary IgA Nephropathy 2023-02-10 07:30
Everest Medicines Announces Top-line Data from Phase I Study of EVER206 on Healthy Subjects in China 2023-01-18 07:30
Everest Medicines Announces New Strategic Plans, Reinforcing Transformation into a Fully Integrated Biopharmaceutical Company 2023-01-03 16:00
Everest Medicines to Hold New Corporate Strategy Online Conference Calls 2022-12-30 08:05
Everest Medicines Announces China NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy 2022-12-30 08:00
Everest Medicines Commences Operations at its mRNA Vaccine Manufacturing Facility, Accelerating Evolution to a Fully-Integrated Biopharma 2022-12-28 08:00
Everest Medicines' Licensing Partner Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis 2022-12-22 08:00
Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone 2022-12-15 08:00
Everest Medicines Announces Major Regulatory Updates in Taiwan and South Korea for Nefecon for the Treatment of Primary IgA Nephropathy 2022-11-28 08:27
Everest Medicines Announces New Drug Application Acceptance by China NMPA for Nefecon for the Treatment of Primary IgA Nephropathy 2022-11-15 08:00
Everest Medicines Announces Partner Providence Reports Positive Top-Line Data from Phase 2 Primary Immunization Trial for mRNA COVID-19 Vaccine Candidate in Adults 2022-10-19 20:15
Everest Medicines Announces Approval of XERAVA® in Hong Kong for the Treatment of Complicated Intra-Abdominal Infections 2022-10-08 08:00
Everest Medicines Receives Approval of Investigational New Drug Application from China NMPA for EVER001, a Novel BTK Inhibitor in Development for Treatment of Renal Diseases 2022-09-26 08:00
Everest Medicines Appoints Rogers Yongqing Luo as Chief Executive Officer to Lead Next Stage of Company Growth 2022-09-19 08:00
Everest Medicines Announces the Departure of CEO, Kerry Blanchard 2022-08-26 07:30
1 2 3 4 5 7